Analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will report sales of $108.07 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for NxStage Medical’s earnings. The highest sales estimate is $109.84 million and the lowest is $106.30 million. NxStage Medical reported sales of $97.30 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The business is scheduled to report its next earnings report on Wednesday, November 14th.

On average, analysts expect that NxStage Medical will report full-year sales of $432.81 million for the current year, with estimates ranging from $429.70 million to $435.91 million. For the next financial year, analysts anticipate that the firm will report sales of $467.80 million, with estimates ranging from $467.30 million to $468.30 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $106.97 million for the quarter, compared to the consensus estimate of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.

A number of brokerages recently weighed in on NXTM. ValuEngine downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. BidaskClub downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, July 20th. Finally, Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th.

Shares of NASDAQ:NXTM traded down $0.05 during mid-day trading on Monday, reaching $28.98. The stock had a trading volume of 314,702 shares, compared to its average volume of 654,908. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -131.73 and a beta of -0.05. NxStage Medical has a twelve month low of $22.70 and a twelve month high of $29.19.

Several large investors have recently made changes to their positions in NXTM. Guggenheim Capital LLC raised its position in shares of NxStage Medical by 106.2% in the 1st quarter. Guggenheim Capital LLC now owns 23,190 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 11,943 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in NxStage Medical during the 1st quarter worth approximately $303,000. Tokio Marine Asset Management Co. Ltd. acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $1,038,000. Steward Partners Investment Advisory LLC raised its holdings in NxStage Medical by 714.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after buying an additional 5,000 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $373,000. Institutional investors and hedge funds own 83.15% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

See Also: What is the S&P 500 Index?

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.